Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
The Prostate Cancer Foundation (PCF) has committed $5 million to support the launch of two new Centers of Excellence that will provide precision medicine treatments to veterans with prostate ... Read more
Veru has completed enrollment for the second portion of a Phase 1/2 study of VERU-111, its investigational therapy for men with metastatic castration-resistant prostate cancer (mCRPC) who failed to ... Read more
Lantheus Holdings has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of PyL, an investigational imaging agent used to locate prostate cancer lesions. The ... Read more
Tolmar Pharmaceuticals maintains a complete inventory of Eligard (leuprolide acetate), its therapy for advanced prostate cancer, and had increased production in response to reports of shortages of other leuprolide ... Read more
The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported symptoms from cancer trials for ... Read more
The use of statins — cholesterol-lowering agents to treat cardiovascular disease — alone or in combination with the diabetes treatment metformin, may increase survival in men with high-risk prostate ... Read more